Financials data is unavailable for this security.
View more
Year on year Lipella Pharmaceuticals Inc had net income fall 77.81% from a loss of 2.60m to a larger loss of 4.62m despite a 144.15% increase in revenues from 184.16k to 449.62k. An increase in the selling, general and administrative costs as a percentage of sales from 122.82% to 479.68% was a component in the falling net income despite rising revenues.
| Gross margin | -- |
|---|---|
| Net profit margin | -816.72% |
| Operating margin | -839.15% |
| Return on assets | -146.02% |
|---|---|
| Return on equity | -171.56% |
| Return on investment | -169.27% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Lipella Pharmaceuticals Inc fell by 1.83m. Cash Flow from Financing totalled 1.34m or 297.27% of revenues. In addition the company used 3.15m for operations while cash used for investing totalled 14.43k.
| Cash flow per share | -0.6038 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.224 |
|---|---|
| Tangible book value per share | 0.224 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.33 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
